Parallax Volatility Advisers, L.P. Sage Therapeutics, Inc. Put Options Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $1.24 Million - $1.61 Million	72,500 Added 537.04%	86,000 $1.86 Million
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $226,125 - $661,230	13,500 New	13,500 $277,000
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $1.37 Million - $1.95 Million	-34,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $1.87 Million - $2.7 Million	34,000 New	34,000 $1.93 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $890,664 - $2.29 Million	-14,800 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $420,870 - $569,880	-3,000 Reduced 16.85%	14,800 $2.08 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $267,990 - $490,950	3,000 Added 20.27%	17,800 $2.83 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $718,172 - $879,008	-5,200 Reduced 26.0%	14,800 $2.09 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $4.58 Million - $5.79 Million	-30,100 Reduced 60.08%	20,000 $3.22 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $3.08 Million - $4.43 Million	50,100	50,100 $3.12 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.